MYOM2 and Miyoshi myopathy: These clinical manifestations are a result of the extensive secretion of the monoclonal immunoglobulin protein (M‐protein), colonization of the MM cells in the bone marrow, and the elaborate interactions between MM cells with the bone marrow microenvironment.[2] The survival rate of MM disease has significantly improved over the last few years due to the development of novel anti‐cancer drugs, however, MM is still considered incurable as patients eventually relapse and develop drug resistance.